Zoetis Inc. (NYSE:ZTS) to Post Q1 2025 Earnings of $1.49 Per Share, Zacks Research Forecasts

Zoetis Inc. (NYSE:ZTS) – Equities research analysts at Zacks Research upped their Q1 2025 earnings per share estimates for Zoetis in a report issued on Wednesday, September 4th. Zacks Research analyst E. Bagri now anticipates that the company will post earnings of $1.49 per share for the quarter, up from their prior estimate of $1.48. The consensus estimate for Zoetis’ current full-year earnings is $5.84 per share. Zacks Research also issued estimates for Zoetis’ Q2 2025 earnings at $1.66 EPS, FY2025 earnings at $6.41 EPS, Q1 2026 earnings at $1.66 EPS, Q2 2026 earnings at $1.79 EPS and FY2026 earnings at $6.98 EPS.

ZTS has been the subject of several other research reports. Stifel Nicolaus restated a “buy” rating and set a $200.00 price target on shares of Zoetis in a research note on Tuesday, August 27th. Piper Sandler upped their price target on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. BTIG Research upped their price target on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Finally, Argus raised Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $217.11.

Zoetis Price Performance

Zoetis stock opened at $189.23 on Friday. Zoetis has a 12 month low of $144.80 and a 12 month high of $201.92. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.45 and a quick ratio of 2.09. The business has a 50 day simple moving average of $181.22 and a 200-day simple moving average of $174.49. The stock has a market capitalization of $85.73 billion, a PE ratio of 36.46, a price-to-earnings-growth ratio of 2.87 and a beta of 0.88.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, topping the consensus estimate of $1.49 by $0.07. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The business had revenue of $2.36 billion during the quarter, compared to analysts’ expectations of $2.31 billion. During the same quarter in the prior year, the business earned $1.41 earnings per share. The company’s quarterly revenue was up 8.3% compared to the same quarter last year.

Institutional Trading of Zoetis

Several large investors have recently bought and sold shares of ZTS. Norges Bank acquired a new stake in Zoetis in the fourth quarter valued at $980,646,000. Price T Rowe Associates Inc. MD grew its holdings in Zoetis by 31.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 13,716,681 shares of the company’s stock valued at $2,707,262,000 after purchasing an additional 3,244,074 shares during the last quarter. Sarasin & Partners LLP boosted its stake in shares of Zoetis by 546.3% during the second quarter. Sarasin & Partners LLP now owns 2,253,590 shares of the company’s stock valued at $390,682,000 after acquiring an additional 1,904,899 shares during the last quarter. Swedbank AB acquired a new stake in shares of Zoetis during the first quarter valued at $210,815,000. Finally, Public Employees Retirement Association of Colorado acquired a new stake in shares of Zoetis during the fourth quarter valued at $242,757,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.